Safety and Efficacy of Coma Induction Following First-Line Treatment in Status Epilepticus
Neurol 97:e564-e576, DeStefano, P.,et al, 2021
Tocilizumab Treatment for New Onset Refractory Status Epilepticus
Ann Neurol 84:940-945, Jun, J.,et al, 2018
Anesthetic Drugs in Status Epilepticus: Risk or Rescue?
Neurol 82:656-664, Sutter, R.,et al, 2014
Drug Treatment of Epilepsy in Adults
BMJ 348:g2546, Schmidt, D. & Schachter, S.C., 2014
Intramuscular Versus Intravenous Therapy for Prehospital Status Epilepticus
NEJM 366:591-600,659, Silbergleit,R.,et al, 2012
Efficacy and Safety of Ketamine in Refractory Status Epilepticus in Children
Neurol 79:2355-2358, Rosati, A.,et al, 2012
Randomized Study of Intravenous Valproate and Phenytoin in Status Epilepticus
Seizure 16:527-532, Agarwal,P.,et al, 2007
Intravenous Sodium Valproate Versus Diazepam Infusion for the Control of Refractory Status Epilepticus in Children: A Randomized Controlled Trial
J Child Neurol 22:1191-1197, Mehta,V.,et al, 2007
Epilepsy in Children
Lancet 367:499-524, Guerrini,R., 2006
Sodium Valproate vs Phenytoin in Status Epilepticus: A Pilot Study
Neurol 67:340-342, Misra,U.K.,et al, 2006
Resective Epilepsy Surgery for Drug-Resistant Focal Epilepsy
JAMA 313:285-293, Jobst, B.C. & Cascino, G.D., 2015
Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930,966,985, Engel,J.,et al, 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Submaxiomal Angioplasty for Severe Intracranial Atherosclerotic Stenosis":Benefit of Revascularization at Last
Stroke 56:e114-e118, Pensatok,U.,et al, 2025
Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis
NEJM 392:2062-2064, Koster,M.J. & Warrington,K.J., 2025
Collaboration on the Optimal Timing of Anticoagulation after Ischaemic Stroke and Atrial Fibrillation:A Systematic Review and Prospective Individual Participant Data Meta-Analysis of Randomised Controlled Trials (CATALYST)
Lancet 406:43-51, Dehbi,K-M.,et al, 2025
A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus
NEJM 393:2198-2209, 2264, Luciano,M.G.,et al, 2025
Treatment Modalities and Outcomes in Brainstem Cavernous Malformations: A Large Multicenter Observational Cohort Study
Stroke 55:1151-1160, Lu,J.,et al, 2024
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
NEJM 391:1015-1027, Al-Samkari,H.,et al, 2024
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
Antiplatelet and Anticoagulant Risk for Select Spine Interventions:A Retrospective Cohort
Pain Med 21:910-917, Ehsanian,R.,et al, 2020
Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
Stroke 50:529-536, Bower, M.M.,et al, 2019
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Surgery for Drug-Resistant Epilepsy in Children
NEJM 377:1639-1647, Dwivedi, R.,et al, 2017
Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke
Stroke 48:e343-e361, Yaghi, S.,et al, 2017
Tocilizumab for Induction and Maintenance of Remission in Giant Cell Arteritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 387:1921-1927,1882, Villiger, P.M.,et al, 2016
Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016
Effects of Aspiring on Risk and Severity of Early Recurrent Stroke After Transient Ischaemic Attack and Ischaemic Stroke: Time-Course Analysis of Randomised Trials
Lancet: 388:365-375, 312, Rothwell, P.M.,et al, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016
Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:DOI:10.1056/NEJMoa1415061, DOI:10.1056 NEJM e1503217, Saver, J.L.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke
NEJM 372:2285-2295,2347, Saver, J.L.,et al, 2015
Thrombectomy within 8 hours after Symptom Onset in Ischemic Stroke
NEJM 372:2296-2306,2347, Jovin, T.G.,et al, 2015
Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015
Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction
Stroke 46:2695-26598, Honeybul, S.,et al, 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
FDA Approves Praxbind, the First Reversal Agent for the Anticoagulant Pradaxa
JAMA 314:2227, , 2015
Anticoagulants for Cerebral Venous Thrombosis
Stroke 45:298-304,8, Cundiff, D.K., 2014
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014